Chembio Diagnostics, Inc.
3661 Horseblock Road
Medford,
NY 11763
United States - Map
Phone: 631-924-1135
Web Site: http://www.chembio.com
| Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and markets rapid diagnostic tests for the detection of HIV antibodies in whole blood, serum, and plasma samples. Its products utilize lateral flow technology and Dual Path Platform (DPP). The companys rapid tests include SURE CHECK HIV 1/2, HIV 1/2 STAT-PAK, HIV 1/2 STAT-PAK Dipstick, and DPP HIV 1/2. It also manufactures rapid tests for Chagas disease, as well as a line of rapid tests for the detection of tuberculosis in humans and certain animal species. Chembio Diagnostics sells its tests to medical laboratories and hospitals, governmental and public health entities, nongovernmental organizations, medical professionals, and retail establishments worldwide. It has collaboration, research, development, licensing, or marketing agreements with United States Centers for Disease Control; Bio-Rad Laboratories N.A.; Bio-Manguinhos division of the Oswald Cruz Foundation; and Inverness Medical Innovations, Inc. The company was founded in 1985 and is based in Medford, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Lawrence A. Siebert , 53
Exec. Chairman, Chief Exec. Officer, Pres, Chairman of Chembio Diagnostic Systems Inc, Chief Exec. Officer of Chembio Diagnostics Inc and Pres of Chembio Diagnostic Systems Inc |
$
291.00K | N/A | Mr. Richard J. Larkin , 54
Chief Financial Officer, Principal Accounting Officer, Sec. and Chief Financial Officer of Chembio Diagnostic Systems Inc |
$
178.00K | N/A | Mr. Richard Bruce , 56
VP of Operations |
$
163.00K | N/A | Mr. Javan Esfandiari , 44
Exec. VP of R&D |
$
231.00K | N/A | Mr. Tom Ippolito , 47
VP of Regulatory Affairs, Quality Assurance & Quality Control |
$
185.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.52% Nasdaq 0.00%
Profile
